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ABSTRACT 
Whatever the outcome, pregnancy provides the opportunity to offer effective contraception to 
couples motivated to avoid another pregnancy. This narrative review summarises the 
evidence for health providers, drawing attention to current guidelines, on which contraceptive 
methods can be used, and when they should be started after pregnancy, whatever its outcome. 
Fertility returns within one month of the end of pregnancy unless breastfeeding occurs. 
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Breastfeeding, which itself suppresses fertility after childbirth, influences both when 
contraception should start and what methods can be used. Without breastfeeding, effective 
contraception should be started as soon as possible if another pregnancy is to be avoided. 
Interpregnancy intervals of at least six months after miscarriage and one to two years after 
childbirth have long been recommended by the World Health Organisation in order to reduce 
the chance of adverse pregnancy outcome. Recent research suggests that this may not 
necessary, at least for healthy women <35 years old. Most contraceptive methods can be used 
after pregnancy regardless of the outcome. Because of an increased risk of venous 
thromboembolism associated with estrogen-containing contraceptives initiation of these 
methods should be delayed until 6 weeks after childbirth. More research is required to settle 
the questions over the use of combined hormonal contraception during breastfeeding, the use 
of injectable progestin-only contraceptives before 6 weeks after childbirth and use of both 
hormonal and intrauterine contraception after gestational trophoblastic disease. The potential 
impact on the risk of ectopic pregnancy of certain contraceptive methods often confuses 
healthcare providers.  The challenges involved in providing effective, seamless service 
provision of contraception after pregnancy are numerous, even in industrialised countries. 
Nevertheless, the clear benefits demonstrate that it is worth the effort.  
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Abbreviations 
CHC combined hormonal contraception 
DMPA depo-medroxyprogesterone acetate 
EP ectopic pregnancy 
GTD gestational trophoblastic disease 
hCG human chorionic gonadotrophin 
IUC intrauterine contraception  
LARC long-acting reversible contraception 
LNG-IUS levonorgestrel releasing intrauterine system 
MEC Medical Eligibility Criteria for Contraceptive Use 
POC progestogen-only contraception  
WHO World Health Organization 
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Key message 
Postpartum contraception saves lives. Most women can use most methods of contraception 
after pregnancy. Because services work in silos, seamless provision of contraception after 
pregnancy, especially immediate postpartum provision of long-acting methods is challenging 
- even in industrialised countries. Nevertheless, the clear benefits demonstrate that it is worth 
the effort. 
 
INTRODUCTION 
 
Contraception saves lives and pregnancy provides an opportunity to offer effective 
contraception to couples motivated to avoid another pregnancy who, in some countries, may 
have very limited contact with healthcare providers.  
 
Not all pregnancies are intended: in 2012 an estimated 40% of all pregnancies worldwide 
were unintended.1  In Scotland in 2004-05, 90% of pregnancies among women requesting 
abortion were clearly unintended; 26% of women attending an antenatal clinic were 
ambivalent about pregnancy intention and 9% had definitely not intended pregnancy when 
they conceived. 2 An estimated 12% of miscarriages and ectopic pregnancies in the UK are 
unintended at conception. 
 
All women should be offered effective contraception after pregnancy, whatever the outcome. 
Yet the opportunity is often missed. Data from 57 low and middle income countries  
demonstrated that 62% of women giving birth in the preceding year did not initiate 
contraception immediately postpartum.3 Even in high income countries, provision of effective 
contraception after delivery is often sub-optimal. Only around 50% of postpartum women in 
a Texan study expressing a preference for either long-acting reversible contraception (LARC) 
or sterilization received their preferred method.4 About 70% of pregnancies occurring within 
one year postpartum in the US are unintended.5 In Scotland, over 13% of parous women 
presenting for induced abortion had been pregnant within the preceding year.6 Repeat 
induced abortion is common worldwide even in countries with excellent contraceptive 
services. In the Netherlands for example, approximately 36% of all abortions are repeats.7  
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Health services everywhere are often fragmented; healthcare providers often work in silos; 
and healthcare providers managing pregnancy simply don’t think about giving about 
contraceptive advice believing that someone else will take care of it. The UK NICE 
Guideline on the management of miscarriage and ectopic pregnancy (EP), for example, does 
not mention asking about the intendedness of the pregnancy or the need for contraception.8  
 
This paper reviews the evidence, and recommendations, for contraception after pregnancy 
ending in either childbirth, induced or spontaneous abortion, ectopic or molar pregnancy. It 
highlights areas of controversy and where indicated makes suggestions for further research. 
 
METHODS 
 
A small group of experts, chosen for their knowledge of the evidence and their familiarity 
with clinical practice in Europe, met to discuss the topic of contraception after childbirth. 
Eight of them prepared oral presentations summarizing the available evidence on which 
contraceptives could be used, and when they should be started, after pregnancy ending in 
childbirth, induced or spontaneous abortion, EP and gestational trophoblastic disease and the 
barriers to their effective provision by healthcare services.  Individual presenters selected the 
most recent systematic reviews available undertaking searches performed in Medline, 
Popline, EMBASE, Cochrane library databases for relevant English language publications 
from 1970 to mid-2018. If topics were not covered by systematic reviews, the same databases 
were used to search for the most recent primary research papers. Each presenter provided a 
written, referenced summary of their presentation which was circulated some four weeks 
before the meeting of the Annual Capri Workshop in Reproductive Medicine (held in 
October 2018). While not formally assessed for quality, the evidence presented was critically 
reviewed and discussed in detail by the workshop participants. Before the end of the meeting 
the participants agreed an outline of the resulting narrative review presented here. 
    
Contraception after childbirth 
 
After childbirth, Cleland and co-workers 9 suggest that on global scale contraception prevents 
some 30% of maternal, and 10% of infant deaths if pregnancies are spaced more than 2 years 
apart. Based on the observation that pregnancies within the first year postpartum have 
increased risks for fetal and early neonatal death, preterm birth, low birth weight and small 
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for gestational age10, in 2007 the World Health Organization (WHO) recommended waiting 
at least two years after childbirth before attempting the next pregnancy. In a report published 
in 2013, WHO further advised that if women wait 2 years to conceive again, under-five 
mortality decreases by 13%, and by 25% following three years delay.11 However, a recent 
study using methodology adjusting for a woman’s predisposition to have these adverse 
pregnancy outcomes, questioned the causal link between interpregnancy intervals and 
adverse pregnancy outcomes.12  In a study of women giving birth in Sweden, short 
interpregnancy intervals (0-3 months) were not causally associated with increased risk of 
stillbirth or early neonatal death.13 A very recent study from British Columbia confirmed the 
lack of association for women under 35 but cautioned against short IBI for older women.14 In 
low and middle income countries where maternal and perinatal mortality and morbidity are 
high and where women may often start, and end, a pregnancy undernourished and anaemic, 
long interpregnancy intervals may be beneficial. In countries where women are commonly 
delaying first childbirth until well into their 30’s, where most are healthy, antenatal care 
routine and paid parental leave is the norm, short interpregnancy intervals may well not be 
harmful should couples choose to start another pregnancy soon after childbirth.  
 
When should contraception start after childbirth?  
 
During pregnancy, high circulating levels of estrogens and progesterone from the placenta 
suppress gonadotrophin levels to 1% of non-pregnant values. Estrogen stimulates pituitary 
lactotrophes resulting in high concentrations of prolactin. Without lactation after delivery, 
concentrations of prolactin decline while those of luteinizing hormone and follicle-
stimulating hormone increase over 30 days leading to the restoration of menstrual cycles. In 
non-lactating women, the first menses after childbirth is often preceded by anovulation, but 
by the third menses over 80% of women have normal ovulatory cycles. In a systematic 
review of the limited data Jackson and Glasier15 reported a mean time of first ovulation 
among non-lactating women between 45 and 94 days postpartum. In 20-71% of women first 
menses was preceded by ovulation and up to 60% of these ovulatory cycles were thought to 
be potentially fertile. Thus, women who do not breastfeed should be advised that without 
contraception pregnancy can occur within the first two months after childbirth. If a woman 
breastfeeds, prolactin concentrations remain elevated and gonadotrophins suppressed. The 
duration of suppressed ovarian activity depends on the breastfeeding pattern. Frequent 
suckling episodes, including at night, prolong ovarian suppression. The introduction of 
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artificial milk and/or solid food coincides with a reduction in the frequency and duration of 
breastfeeding episodes and as the suppressive effect of suckling wanes so ovarian activity 
resumes. In a study of 27 breastfeeding mothers, first menses occurred at a mean of 32.5 
weeks after childbirth, preceded by ovulation in 33% 16. Breastfeeding influences not only 
when contraception should be started, but which methods can be used. The formalised 
Lactational Amenorrhoea Method (LAM) advises that another method of contraception 
should be started when the baby reaches six months, or sooner if menses returns or 
exclusive/almost exclusive breastfeeding stops (and supplements are introduced). Two 
controlled studies of LAM users at 6 months postpartum reported life table pregnancy rates of 
0.45 and 2.4%, while six uncontrolled studies reported pregnancy rates from 0 -7.5%.17  
 
Which methods can be used after childbirth? 
 
Hormonal contraception: The relative risk of venous thromboembolism is increased 
approximately 5-fold in pregnancy, and 60-fold in the puerperium, particularly during the 
first three weeks. The risk is theoretically increased by using combined hormonal 
contraception (CHC). Women are advised to wait at least three (and preferably six) weeks 
before starting CHC.18 Women with additional risk factors for venous thromboembolism  
must wait 6 weeks. Low-dose progestogen-only methods are not associated with any 
increased risk of venous thromboembolism and, while limited evidence suggests a possible 
small increased risk of thrombosis in association with use of Depo Provera, all methods are 
considered safe (Medical Eligibility Criteria for Contraceptive Use (MEC) category 1) for 
post-partum women.  
 
WHO has concerns about the theoretical risk of CHC on breastfeeding continuation or 
exclusivity, and about old reports of possible effects on infant growth or health and advises 
that CHC should not be used before 6 months postpartum by breastfeeding women, unless no 
other method is available or acceptable (WHO MEC, Category 3).18 However, most trials 
published after 2005 do not report any significant impact of CHC on breastfeeding duration, 
breast milk composition, or infant growth 19  and the UK20  and US guidance 21) recommend 
that the benefits outweigh the theoretical risks of CHC use after 6 weeks postpartum 
(Category 2) among breastfeeding women.  
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Despite progestogen-only contraception (POC) having no apparent direct impact on 
breastfeeding, child health or development 22, WHO still expresses theoretical concern about 
the potential exposure of the neonate to depo-medroxyprogesterone acetate (DMPA) and 
norethisterone enanthate (NET-EN) and recommends delaying initiation of these injectable 
POC methods until after 6 weeks postpartum. The US and UK do not recommend any such 
delay. Progestin-only pills and implants can be started immediately after childbirth regardless 
of infant feeding.  
 
Intrauterine contraception (IUC): Copper intrauterine devices (Cu-IUDs) and the 
levonorgestrel releasing intrauterine system (LNG-IUS) can be inserted during cesarean 
section or within 48h of vaginal delivery. WHO18 does not recommend insertion between 48h 
and 4 weeks after childbirth because of higher rates of expulsion compared with later interval 
insertion, however the US MEC 21considers that the benefit of insertion at this time 
outweighs the risks. A recent systematic review and metanalysis review reported expulsion 
rates 1.9% for interval insertion; 10.0% for immediate post-placental insertion and almost 
30% for insertion between 10 minutes and four weeks. Rates of expulsion were higher for the 
LNG-IUS than copper devices inserted before 4 weeks (adjusted RR 1.91 95% CI 1.50-2.43) 
and after vaginal delivery were five times higher than after insertion at the time of cesarean 
section.23 
 
The risk of uterine perforation is increased throughout lactation and is highest up to 6 months 
after delivery for both copper intrauterine devices and LNG-IUS (six-fold increase, 7/1000 
insertions,24 underlining the importance of postpartum placement of intrauterine 
contraception being done by experienced healthcare providers. IUC insertion should be 
avoided in women with postpartum sepsis. 
 
Other methods: Condoms can be used as soon as needed. Diaphragm or cap fitting should 
wait until 6 weeks postpartum, when involution of the cervix is complete. Fertility 
awareness-based methods can be used when the menstrual cycle has resumed. Oral 
emergency contraception, if required should be offered from 21 days postpartum, but 
ulipristal acetate is not recommended in breastfeeding women. Regret and dissatisfaction may 
be more common following sterilisation done immediately postpartum and should be done 
only after careful counselling. 
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Contraception after miscarriage (spontaneous abortion) 
 
Miscarriage is the commonest adverse pregnancy outcome with estimated rates of 8-20%. In 
the UK, 10 to 15% of all pregnancies end in miscarriage and an estimated 12% of these result 
from unintended pregnancies. 
 
When should contraception start after miscarriage? 
 
First menses occurs at a mean of 29 days after miscarriage, with ovulation preceding menses 
in all women.25 Thus, if pregnancy is not desired contraception should be started 
immediately. The World Health Organisation recommends waiting at least six months before 
trying to conceive again. However, a recent study26, using Scottish national data, showed that 
women with an interpregnancy interval of <six months were less likely to have another 
miscarriage (adjusted odds ratio 0.66, 95% confidence interval 0.57 to 0.77), preterm delivery 
(0.89, 0.81 to 0.98), or infant of low birth weight (0.84, 0.71 to 0.89). A systematic review of 
16 studies27  reached similar conclusions. Current evidence suggests that, if pregnancy is 
desired, it is not necessary to use contraception after miscarriage, and couples wishing to 
conceive again should be advised to try as soon as they feel ready.  
 
What contraceptive methods can be used after miscarriage? 
 
All methods of contraception can be used without any restriction after miscarriage, and the 
most effective method acceptable should be offered. The risk of expulsion of intrauterine 
methods may be higher when inserted after a second trimester abortion (versus first 
trimester).18 Diaphragms and caps should not be fitted before 6 weeks after second trimester 
miscarriage to allow for complete involution of the cervix. 
 
Contraception after induced abortion. 
 
About 90% of women ovulate in the first month after first trimester abortion and more than 
50% resume sex within two weeks .28 Contraception should therefore be started immediately 
regardless of gestation, unless sepsis is present, and all methods can be used .18  
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Repeat abortion is common. LARC methods have been repeatedly shown to reduce the risk 
of repeat unintended pregnancy after induced abortion.29 IUC can be inserted at surgical 
abortion or following expulsion of the fetus at medical abortion and early insertion increases 
uptake after both medical and surgical abortion.28,30 Increasing use of medical abortion and 
home administration of misoprostol as well as self-assessment of the outcome of the abortion 
complicates contraceptive provision, especially LARC. Fewer US women having medical 
abortion had an IUD insertion compared with those undergoing surgical abortion31 Initiation 
of LARC is being explored at ever earlier intervals. There are theoretical concerns about a 
possible interaction between progestins and the anti-progesterone mifepristone used for 
medical abortion. While insertion of a POC implant at the time of mifepristone administration 
does not impair the efficacy of early medical abortion 32, administration of DMPA with 
mifepristone increased the risk of failed medical abortion (ongoing pregnancy) compared 
with DMPA administration delayed until after the abortion (3.5% vs 0.9%).33 A very recent 
study suggested that giving DMPA at the time of misoprostol administration had no effect on 
ongoing pregnancy rates. 34 A recent randomized controlled trial demonstrated an increased 
risk of partial expulsion with fast-track (≤3 days) insertion of the LNG-IUS compared with 
insertion 2-4 weeks after misoprostol administration (expulsion rates 12-28 vs. 2-4%).30, 35 
However, use of LNG-IUS was higher and pregnancy rates lower at one year if the device 
had been inserted immediately.36 As with IUC insertion immediately after childbirth, from a 
public health perspective the advantages of immediate IUC insertion after medical abortion 
(improved uptake and reduced repeat pregnancy rates) appear to outweigh the disadvantage 
of increased expulsion rates. The IUC can be replaced provided expulsion is recognised.  
 
Besides the contraceptive methods being offered, how the service is being delivered is of 
importance. Provision of LARC by the same unit providing the abortion care decreased the 
risk of subsequent abortion.29 
 
Contraception after ectopic pregnancy. 
 
Ectopic implantation of the embryo occurs in 1-2% of confirmed pregnancies and accounts 
for at least 6% of pregnancy-related deaths worldwide. With earlier diagnosis and improved 
treatment, modern management emphasises preserving fertility. There is no evidence of a 
delay in return to fertility after EP.37 Thus, women who want to avoid another pregnancy 
should start effective contraception immediately. For women wishing to conceive, the chance 
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of the next pregnancy being intrauterine is 60-70% regardless of the mode of treatment 37, but 
the recurrence rate of EP is 10-15% after one EP, and 30% after a second.38 
 
All methods of contraception reduce the risk of pregnancy, and women who have had EP 
may use any method.18 No contraceptive methods increase the risk of EP but some, 
depending on the mode of action, may do a better job of preventing it, a fact that confuses 
many providers. The absolute risk of EP during contraceptive use is very low. A recent 
systematic review of implants and injectable POC39concluded that these methods are highly 
effective at preventing any pregnancy, but that levonorgestrel-releasing implants (which 
inhibit ovulation inconsistently) have a higher rate of EP when they fail compared with 
etonorgestrel-releasing implants or DMPA, both of which inhibit ovulation consistently. Low 
dose oral POCs, which inhibit ovulation inconsistently and alter tubal motility, significantly 
reduce the risk of EP compared with condoms or no method.20 Failure of emergency 
contraception is not associated with an increased risk of EP. While intrauterine contraceptives 
are the most effective reversible contraceptives, when pregnancy occurs with an IUD or 
LNG-IUS in situ there is an increased risk of EP and assessment by ultrasound scan should be 
expedited. The cumulative probability of EP 10 years after female sterilization has been 
reported as 2.4/1000 procedures.40  
 
If EP is managed with methotrexate, contraception should be used to avoid a theoretical risk 
of teratogenesis. Manufacturers recommend contraception for six months after methotrexate 
treatment stops, the UK Royal College of Obstetricians and Gynaecologists recommends 
three months.20 Limited evidence suggests that conception within three months of 
methotrexate use is not associated with an increased risk of fetal malformation20, but 
pregnancies occurring before 6 months should nevertheless be carefully screened. 
 
Contraception after gestational trophoblastic disease (GTD, molar pregnancy) 
 
The risk of malignant disease following surgical evacuation of a complete mole is 15-20% 
and after incomplete or partial mole 0.5-5% .41 Serum human chorionic gonadotrophin (hCG) 
monitoring is pivotal to managing GTD, allowing early identification of malignancy and 
reliable follow-up after chemotherapy. Conception during the monitoring phase raises hCG 
and considerably complicates the management, causing delayed diagnoses or misdiagnoses of 
malignancy. Women becoming pregnant within 6 months after diagnosis of molar pregnancy 
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(or 12 months after chemotherapy for malignant disease) have an increased risk of morbidity 
and mortality.41 For this reason, contraception is mandatory, and should be started 
immediately as ovulation returns rapidly after uterine evacuation. Up to 12-23% of women 
conceive before the scheduled end of the monitoring period suggesting the contraceptive 
method used should be highly effective. Initial studies of hormonal contraception in women 
with a recent diagnosis of GTD suggested an increased risk of developing malignancy. 
Trophoblastic cells have sex steroids receptors whose proliferative activity can be modulated 
by reproductive hormones. Recent epidemiological evidence is reassuring. A systematic 
review concluded a lack of causality between hormonal contraception and GTD42 and two 
large case series not included in the review failed to demonstrate any detrimental effect of 
hormonal contraception.43 To date there is no evidence to contraindicate hormonal 
contraception during the clinical management of women with GTD. All hormonal 
contraceptives can be used without any restrictions after GTD, but, despite no evidence of 
any detrimental effect on disease outcome, intrauterine contraception is contraindicated until 
after hCG levels have returned to normal.18 Among clinicians there appears to be a natural 
reluctance to insert a device into a uterus which may be more vulnerable to perforation and, 
perhaps, haemorrhage. 
 
Lessons for improving provision of contraception after pregnancy 
 
The benefits of providing effective contraception after pregnancy are clear.  
Fertility resumes rapidly after pregnancy regardless of outcome. If contraception is left until a 
follow-up appointment (which many women fail to attend 28, 44 many women are already at 
potential risk of pregnancy and those choosing LARC methods often face yet further delays 
accessing trained providers.   
 
Educational interventions about contraceptive use after childbirth, including giving women 
advice antenatally, are generally of low quality. Limited evidence suggests that some 
educational interventions can increase uptake of contraception - including the most effective 
methods - after childbirth.45,46  In Scotland, information given by midwives at an antenatal 
visit has been part of the pathway of a successful initiative to increase LARC uptake after 
delivery.47 
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Peri-abortion information-giving alone does not appear to influence uptake of LARC or risk 
of further unplanned pregnancy 48; it should be part of a pathway to facilitate access to and 
initiation of contraception. 
 
Visual and verbal information are acceptable to women after both childbirth and abortion.49,50 
The use of pre-prepared scripts saves time and ensures consistent information and DVDs or 
web-based information is becoming increasingly acceptable.  Most women given information 
about the contraceptive implant using a DVD had knowledge recall as good as with a face-to-
face consultation and found the DVD helpful and easy to understand.51 Women find 
contraceptive counselling acceptable during the abortion consultation47 (Purcell et al., 2016). 
Telephone counselling about contraception, separated from the abortion consultation is an 
alternative model.52 
 
The “best” contraceptive method after pregnancy is the one that the informed individual 
woman considers most appropriate for her - and which she is therefore most likely to 
continue.  Information should be provided about all suitable contraceptives and should 
include discussion about the comparative efficacy of all available methods. The least 
effective methods include male and female condoms (failure rate 18-20% in the first year of 
use), spermicides (failure rate 28%) and fertility-awareness based methods (failure rate 24%). 
Diaphragms have a moderate failure rate (12%/year) while hormonal methods which rely on 
correct and consistent use have failure rates of between 5 and 8% per year. LARC clearly 
provides the best protection against pregnancy with failure rate less than 1% per year and 
satisfaction with the most effective LARC methods can be high even for women whose initial 
preference is for a short-acting method.53  
 
Barriers to provision. 
 
Many barriers limit provision of contraception after pregnancy, some more easily overcome 
that others. Lack of knowledge, appropriate training and the ability to prescribe, among the 
cadre of staff who manage the outcome of the pregnancy whether childbirth, miscarriage or 
induced abortion often deters them from taking responsibility for contraceptive provision. 
Lack of staff trained in insertion techniques is a significant barrier to provision of LARC after 
childbirth 54and after abortion. Because services work in silos, seamless provision of 
contraception after pregnancy, especially immediate postpartum provision of long-acting 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
methods is challenging - even in industrialised countries. For example, negotiating agreement 
over who should follow-up women after postpartum or post-abortion IUC insertion has 
proven surprisingly challenging in the UK. 
 
It is worth being imaginative and flexible if it facilitates provision of an effective method 
which ensures prevention of unwanted pregnancy, particularly in vulnerable groups like 
adolescents, single mothers or drug-users. Post-natal insertion of POC implants in women’s 
homes was evaluated in a cohort of 40 Scottish women; the service, provided by specially 
trained “contraceptive champion” community midwives was highly acceptable to the 
women.55  
 
CONCLUSION 
 
The provision of contraception after pregnancy is not complicated but in the process of 
managing the pregnancy itself, it is something which is often forgotten completely or is rather 
poorly managed. Clear, evidence-based advice on which methods can be used and when they 
should be started is readily available on-line from the WHO, UK  and US MEC.18,20,21  The 
benefits of doing a good job are clear. Ensuring the availability of all contraceptive methods, 
facilitating uptake and ensuring correct and consistent use and method continuation is always 
challenging but women/couples with a recent pregnancy are often highly motivated.   
Evidence is beginning to emerge on how best to organise services to allow provision of the 
most effective method acceptable to couples/women after pregnancy (whatever the outcome) 
and to do so at a time which is both convenient for the user and ensures high rates of method 
continuation and satisfaction. It takes flexibility and very collaborative thinking on the part of 
service providers, but it is an investment which is well worth making.  
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APPENDIX 
The annual Capri Workshop [October 1-2, 2018] discussed “Contraception after pregnancy”. 
The lecturers included: Siladitya Bhattacharya (Head of the School of Medicine, Cardiff 
University School of Medicine, College of Biomedical and Life Sciences, Cardiff, UK), 
Johannes L.H. Evers (Professor of Obstetrics & Gynaecology Research Institute GROW, 
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Maastricht University and Academisch ziekenhuis Maastricht, Dept. Obstetrics & 
Gynaecology, Maastricht, The Netherlands), Kristina Gemzell-Danielsson (Chair Division of 
Obstetrics and Gynecology, Dept. of Women´s and Children´s Health, Karolinska Institutet, 
WHO-centre, Karolinska University Hospital, Stockholm, Sweden), Anna Glasier (Simpson 
Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK), Sarah Hardman 
(Specialty Doctor SRH and Deputy Director of the FSRH Clinical Effectiveness Unit, 
Chalmers Centre, Edinburgh, UK), Oskari Heikinheimo (Department of Obstetrics and 
Gynaecology, University of Helsinki and Kätilöopisto Hospital, Helsinki University Central 
Hospital, Helsinki, Finland), Carlo La Vecchia (Department of Clinical Sciences and 
Community Health, Università degli Studi di Milano, Milan, Italy), Edgardo Somigliana 
(Clinica Ostetrica e Ginecologica, IRCCS Ca' Granda Foundation, Maggiore Policlinico 
Hospital, Milano, Italy). The chairs included: David T. Baird (Centre for Reproductive 
Biology, University of Edinburgh, UK), PierGiorgio Crosignani (IRCCS Ca' Granda 
Foundation, Maggiore Policlinico Hospital, Milano, Italy), Eva Negri (Department of 
Biomedical and Clinical Sciences, Università degli Studi di Milano, Milano, Italy), Annibale 
Volpe (Dipartimento Integrato Materno Infantile, Università di Modena, Modena, Italy). 
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